Flatiron Health and DeepScribe are partnering to bring AI documentation to clinicians using Flatiron’s OncoEMR. They will incorporate DeepScribe’s oncology-specific ambient AI into OncoEMR, which contains 4,200 providers. This will make DeepScribe the first ambient AI solution partner for Flatiron Health.
“It is important to take a risk-based approach to developing and deploying AI directly into the healthcare ecosystem,” said Stephen Speicher, MD, Flatiron’s head of clinical oncology and patient safety. “In the AI Strategic Plan, HHS appropriately recognizes the risks that can stem from using AI in high-risk clinical workflows, including diagnosis and treatment, as well as apprehensions about the topic felt by some providers and patients.”
Speicher is a member of the Electronic Health Record (EHR) Association’s AI Task Force. Among other things, they talk about the impact of incorporating these AI-enabled capabilities into the point of care and the work that’s being done to ensure they are used safely and ethically. The EHR Association’s AI Task Force recently published a blog outlining his perspective on HHS’s strategic framework and roadmap for AI in healthcare.
DeepScribe calls itself “The ambient AI of choice for specialty care.” Flatiron Health is a “leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology.”
By integrating DeepScribe’s oncology-specific AI with OncoEMR, over 4,200 providers—across more than 800 community-based cancer care locations across the U.S.—can significantly reduce the time they spend charting, and cultivate a more personal connection with patients. In recent feedback from oncologists, 91% called DeepScribe easy to use, with adoption rates over 80% within large oncology groups.
“We are thrilled to partner with Flatiron and help them continue having a meaningful impact on cancer care,” said Matthew Ko, DeepScribe CEO and co-founder. “We want to ensure that their clinicians can make the most of every encounter, with the information and time they need to truly connect with the patient. The seamless integration with OncoEMR helps make that happen.”
DeepScribe hopes this partnership will build on traction solidifying DeepScribe as a favored ambient AI scribe for oncology, with nearly 1,000 oncologists using the platform each day for care documentation.
“Technology—including AI tools—are transforming the point of care, improving outcomes for both patients and the clinicians who serve them,” said Nina Chavez, VP of strategic partnerships and alliances, Flatiron Health. “We’re excited to bring DeepScribe’s AI documentation tools to our network of providers, reducing the administrative burden on providers and enabling more meaningful time with patients.”
DeepScribe’s ambient AI is optimized for oncology by understanding the workflow, terminology, and subtleties of cancer care, automatically creating a structured clinical note. This includes intelligently pulling in key contextual information from previous visits, understanding interval history based on the current conversation, and organizing the note’s plan with relevant ICD-10 diagnosis codes.
Each AI-generated note automatically populates the patient chart within OncoEMR for clinician review and signoff, streamlining the workflow even further and giving clinicians more time in their day—and more time for care.
“Oncology care involves complex decision-making and information management,” said Dean Dalili, MD, DeepScribe chief medical officer. “Our teams have worked closely with oncologists for our AI to capture the nuances and details of a cancer care conversation. Oncologists tell us how well DeepScribe captures terminology, medication names, care plan details. We look forward to each Flatiron clinician benefitting—and in turn, each of their patients benefiting.”
